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Introduction
Given the potential of cell-based products, including
stem/progenitor cells and immune cells, there is a global
effort to introduce these therapies into the clinic to
correct organ dysfunctions, to treat cancer and to ab-
rogate autoimmune diseases and a wide variety of
pathological conditions [1–3]. Relatively easy access
to these cells, obtained from marrow, adipose, cord
blood and other human tissues, provides tremen-
dous opportunity for translational research, particularly
for indications with no satisfactory medical solution
for patients with “unmet medical needs.” Prenatal and
adult stem cells (including induced pluripotent stem
cells have significant potential to rebuild tissues and
correct dysfunctional organs in human diseases. In par-
allel, certain populations of adult stem cells—notably
mesenchymal stromal cells (MSC)—can also have
modulatory actions in the absence of participating in
structural tissue repair [4]. MSCs offer additional ther-
apeutic benefits, of which the precise mechanisms of
action are still under investigation. Similarly, the ability
to isolate, modify and stimulate immune cells prompted
their use within adoptive immunotherapy to treat
cancer [5]. In the past two decades, technological ad-
vances have provided commercially available cell-
manufacturing devices, reagents and delivery tools that
enable processing, selection, expansion and storage of
cells at a relatively low cost. Although these attri-
butes form the basis for progressive acceleration in the
field, they have also been associated with an in-
creased early use of these therapies before being vetted
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within appropriate and adequate risk-benefit analy-
ses.The use of cell-based interventions masquerading
as “proven therapies” outside of approved clinical trials
is a matter of even greater concern, as better under-
standing of several biological functions for many cell
types in pre-clinical settings and in early controlled
clinical trials is still needed.
Many of the cell types being investigated are readily
accessible. Furthermore, there are fewer limitations
related to intellectual property rights or cell-based tech-
nology methods than those customarily present during
the development of small- and macro-molecule drugs.
Although these freedoms promote robust, legitimate
research and development, it has also led to the par-
allel development of clinics worldwide that offer cellular
therapies with questionable safety or efficacy data or
unclear scientific rationale for the treatment of a variety
of diseases. This has led to vulnerable patients sub-
jecting themselves to unproven cellular therapies in
an environment with inadequate regulatory over-
sight or reliable information about potential risks or
benefits [6,7].
How to define (and recognize) unproven cell therapies
The definition of unproven cell therapies is broad and
could also be related to legitimate in-process re-
search activities aimed to improve and verify certain
cell-based approach hypotheses. Although new inves-
tigational medicinal products are tested under duly
authorized clinical trials, many remain unproven or
insufficiently proven. Unfortunately, many unproven
or insufficiently proven cell therapies have been pro-
posed to patients as “treatments or therapies” for a
specific financial cost and without recognized biolog-
ical and medical proofs of safety and efficacy (ie,
without a positive benefit-risk assessment in place).
Most of these therapies are offered outside of prop-
erly authorized channels and fall outside the realm of
conventional clinical trial models, supervised and moni-
tored by regulatory agencies (with the appropriate
exceptions being compassionate use, or hospital ex-
emptions). Although the legal definition of authorized
cell therapy resides in the governing hands of each cou-
ntry’s regulatory authority for drugs and therapeutic
products, narrowing the scope to a handful of char-
acterizations may assist the cell-therapy community
to initiate the process of reaching a universal defini-
tion.The following series presents a starting point for
clarification of defining an unproven cell therapy
(Table I).
The lack of (reliable) information for patients on
unproven cell therapies may be inversely proportion-
al to the price for these treatments that are generally
associated with a considerable economical and psy-
chological impact for patients and their families.They
generally take place in countries where such thera-
pies are not regulated, and, for this reason, those
practices have been dubbed “stem cell medical
tourism” [8]. Recently, these practices have been oc-
curring with greater frequency in countries where
regulation is stricter but loopholes exist in the regu-
latory policies [9].
Most of these unproven cell therapy scenarios
provide very little local follow-up for treated pa-
tients. Since the clinicians involved are not required
to provide data on their patients, few authentic reports
of the success or failure of these therapies exist for ap-
propriate peer review and regulatory oversight. Apart
from being potentially unethical and possibly causing
harm, unproven cell therapies may negatively affect
the legitimate development of cell-based therapies.
Raising the interest on unproven cell therapies
Therefore, it is in the interest of the Inter-
national Society for Cellular Therapy (ISCT;
www.celltherapysociety.org) and other stakeholders
within this field to raise awareness of unproven cell
therapies. As a professional scientific organization, the
ISCT maintains the power and authority to define how
the world will develop cell therapy principles and pro-
cesses. There is a particular need to determine what
methods will be considered scientifically sound and
ethically acceptable in this area of development.
The current environment is complicated to say the
least. Varied circumstances exist throughout differ-
ent parts of the world, thus creating diverse logistical,
regulatory, social, economic and ethical challenges to
developing this area of medicine. Furthermore, stem
cells hold a nearly magical role in the eyes of pa-
tients.This leads clinicians to have an unusual amount
of responsibility to properly communicate and mod-
erate treatment expectations. To provide proper
informed consent, patients must have a realistic un-
derstanding of cell therapy. How healthcare is
Table I. Characterization of unproven cell therapies.
□ Unclear scientific rationale to suggest potential efficacy
□ Lack of understanding on the mechanism of action and/or the
biological function to support clinical use
□ Insufficient data from in vitro assays, animal models and
clinical studies regarding the safety profile to support the use
in patients
□ Lack of a standardized approach to confirm product quality
and ensure consistency in cell manufacturing
□ Inadequate information disclosed to patients to enable proper
informed consent
□ Use within non-standardized or non-validated administration
methods
□ Uncontrolled experimental procedures in humans
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approached can differ by country. Adding to the com-
plexity and intricacy of the situation includes an honest
acknowledgment of the varying motivations among
stakeholders within the field, from the idealistic sci-
entist to the financially motivated capitalist, opinions
color the landscape in shades of gray. Unfortunately,
there are also individuals who use this opportunity to
prey on vulnerable patients. As such, there is need to
find common ground between all involved stakehold-
ers to promote greater cooperation and a balanced
approach that facilitates the development of safe and
effective therapies and the patients’ access to them
without causing undue risks to patients or exploiting
their vulnerability.
This text is an open, updatable document intend-
ed to be actively shared with other professionals
(ie, bioethicists, scientific organizations and patient
associations) as we work together to define and con-
structively discuss these issues and forge a path forward.
With hastened immediacy, we also hope to promote
a strategy for communication with patients consider-
ing unproven cell therapy as a treatment option. It is
imperative that these people have the intellectual liberty
to make an informed decision.
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